Key Highlights

  • Diluted earnings per share attributable to the company were USD 10.44 for the quarter ended September 30, 2026, up from USD 8.92, a rise of about 17% (calculated).
  • Revenues increased 8% to USD 110,957 million, Gross Profit grew 12% to USD 3,956 million, and Operating Income reached USD 1,604 million versus USD 1,407 million.
  • Net income attributable to the company was USD 1,218 million against USD 1,110 million, while diluted shares fell to 116.7 million from 124.4 million.
  • In six months the company returned USD 3.6 billion to shareholders, and the board raised the quarterly Dividend to USD 0.94 per share from USD 0.82.

Higher Volumes and Fewer Shares Lift Second-Quarter Earnings

McKesson (NYSE:MCK) filed its fiscal second-quarter 2027 report on November 4, 2026, covering the three months to September 30. Revenues rose 8% to about USD 111 billion (USD 110,957 million), and Gross Profit Margin edged up 14 basis points to 3.57%. Operating expenses grew 10% to USD 2,352 million, including USD 85 million of restructuring, Impairment and related charges, up from USD 63 million. Interest expense climbed to USD 105 million from USD 74 million, and income tax expense was USD 266 million. In the North American Pharmaceutical segment, operating profit increased on higher distribution volumes and a share of antitrust legal settlement proceeds, while Oncology and Multispecialty benefited from specialty pharmaceutical growth.

Medical-Surgical Separation, Apollo Investment and New Debt

The company plans to separate its Medical-Surgical Solutions Business into an independent company. On June 1, 2026, Apollo Funds invested about USD 1.25 billion in convertible preferred Equity of that business for an interest of about 13%. Net charges tied to the planned separation were USD 42 million within the segment and USD 4 million at corporate in the quarter. Subsidiaries in that segment also arranged term loans and a revolver, with net proceeds of USD 3.2 billion, and McKesson (NYSE:MCK) signed a USD 5.0 billion unsecured Credit Facility maturing in 2031. Net Income attributable to noncontrolling interests was USD 78 million, including a USD 17 million Redemption value adjustment. Other income, net was USD 63 million, and pre-tax income reached USD 1,562 million against USD 1,395 million.

Buybacks, Dividend Increase and Regulatory Uncertainty

For the six months, McKesson (NYSE:MCK) spent USD 3.4 billion on repurchases and USD 198 million on dividends, leaving USD 4.3 billion of authorization after the board approved an additional USD 5.0 billion on April 29, 2026. Six-month diluted EPS was USD 15.53 versus USD 15.16, a smaller increase because of USD 391 million of redemption value adjustments in the first quarter. The filing flags risks from regulatory change, including drug pricing and the federal 340B program. It gives no numeric guidance in the extract reviewed, so the results stand as reported figures only. Management notes that the scope and timing of policy changes are difficult to predict.

Where Things Stand

Higher drug distribution volumes and a shrinking share count did the heavy lifting. McKesson (NYSE:MCK) grew Revenue 8% and operating income about 14% (calculated), while Buybacks cut diluted shares by roughly 6% (calculated), turning net income growth of about 10% (calculated) into EPS growth of about 17% (calculated). Rising interest expense and separation costs are offsets. Watch the Medical-Surgical separation timetable, the use of new debt, regulatory changes affecting drug pricing, and progress on the USD 4.3 billion of remaining buyback authorization.